Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920215 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
A Phase 2 study of Long Term Follow up Dry Eye Disease, sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 3
- Study locations
NCT03920215 is a Phase 2 study of Long Term Follow up Dry Eye Disease that has completed, run by Oyster Point Pharma. The registered enrollment target is 101 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT03920215, a Phase 2 study of Long Term Follow up Dry Eye Disease, has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
Conditions Studied
Interventions
- DRUG OC-01 Low Dose, 0.12 mg/mL
- DRUG OC-01 Mid Dose, 0.6 mg/mL
- DRUG OC-01 High Dose, 1.2 mg/mL
- DRUG Placebo (vehicle) nasal spray
Study Locations (3)
California
- Newport Beach - Newport Beach
Indiana
- Indianapolis - Indianapolis
Massachusetts
- Andover - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03920215
The ClinicalTrials.gov registry entry for NCT03920215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long Term Follow up Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions - of which OC-01 Low Dose, 0.12 mg/mL is the first listed.
NCT03920215 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03920215 about?
NCT03920215 is a clinical study titled "Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease". The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
What is the current status of trial NCT03920215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2018-08-15. Estimated completion is 2019-09-20.
What conditions does trial NCT03920215 study?
This clinical trial studies the following conditions: Long Term Follow up Dry Eye Disease.
What interventions are being tested in trial NCT03920215?
The interventions under investigation include: OC-01 Low Dose, 0.12 mg/mL (DRUG), OC-01 Mid Dose, 0.6 mg/mL (DRUG), OC-01 High Dose, 1.2 mg/mL (DRUG), Placebo (vehicle) nasal spray (DRUG).
Who is sponsoring clinical trial NCT03920215?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03920215 being conducted?
This trial has 3 study locations across California, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.